I-Mab will be presenting preclinical data on a newly developed, novel asset TJ-CD4B, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020. TJ-CD4B, also known as ABL111, is a Claudin 18.2 and 4-1BB bispecific antibody jointly developed with ABL Bio Inc. TJ-CD4B is from I-Mab's emerging bispecific antibody portfolio designed to create novel drug molecules that synergize two pathways for better clinical efficacy. By linking with an antibody against Claudin 18.2, a gastric- and pancreatic-specific cancer antigen, TJ-CD4B/ABL111 is uniquely structured to supercharge T cells in a Claudin 18.2-dependent manner, enhancing anti-tumor immunity while potentially minimizing toxicity.

The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab's bispecific antibody portfolio, reflecting Company's discovery and CMC capabilities to engineer novel molecules with combined target specificities. I-Mab plans to advance more novel bispecific antibodies towards clinical development stage, following the lead of TJ-CD4B/ABL111.